Pancreatic Cancer Research

ResearcherGeneral Hospital of Shenyang Military RegionNo recent work listed

Xiaozhong Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6397-0501; OpenAlex author ID A5090644360. Sources: OpenAlex.

Their work

Papers
19 (first author 11, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 4 papers · 2014: 4 papers · 2015: 4 papers · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper

Papers 19

  1. Effects of KAI gene expression on ferroptosis in pancreatic cancer cells. First author DOI 10.3892/mmr.2020.11802↗
  2. KAI1 reverses the epithelial-mesenchymal transition in human pancreatic cancer cells. First author DOI 10.1016/j.hbpd.2019.03.004↗
  3. Portal Hypertension in a Patient With Recurrent Pancreatic Cancer After Radiotherapy and Systemic Chemotherapy. Last author DOI 10.1016/j.jceh.2017.11.005↗
  4. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer in vitro. First author DOI 10.3748/wjg.v23.i5.817↗
  5. Src/STAT3 signaling pathways are involved in KAI1-induced downregulation of VEGF-C expression in pancreatic cancer. First author DOI 10.3892/mmr.2016.5093↗
  6. Pancreatic cancer: diagnosis and treatments. Co-author DOI 10.1007/s13277-015-3223-7↗
  7. Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with t… First author DOI 10.1177/1535370215571884↗
  8. MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Co-author DOI 10.18632/oncotarget.3885↗
  9. Endocrine gland‑derived vascular endothelial growth factor modulates proliferation, apoptosis and migration in pancreatic cancer cells. First author DOI 10.3892/mmr.2015.3340↗
  10. Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer. First author DOI 10.1007/s13277-014-1687-5↗
  11. Prognostic significance of cyclooxygenase-2 protein in pancreatic cancer: a meta-analysis. First author DOI 10.1007/s13277-014-2260-y↗
  12. KAI1 inhibits lymphangiogenesis and lymphatic metastasis of pancreatic cancer in vivo. First author DOI 10.1016/s1499-3872(14)60012-6↗
  13. Effect of PTEN and KAI1 gene overexpression on the proliferation, metastasis and radiosensitivity of ASPC‑1 pancreatic cancer cells under hypoxic conditions. Last author DOI 10.3892/mmr.2014.2404↗
  14. Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA. First author DOI 10.1016/j.vaccine.2013.07.055↗
  15. Beclin1 inhibition promotes autophagy and decreases gemcitabine-induced apoptosis in Miapaca2 pancreatic cancer cells. Co-author DOI 10.1186/1475-2867-13-26↗
  16. Role of endoscopic ultrasound in treatment of pancreatic cancer. Co-author DOI 10.4103/2303-9027.121238↗
  17. Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer. Co-author DOI 10.4251/wjgo.v5.i2.20↗
  18. KAI1 inhibits HGF-induced invasion of pancreatic cancer by sphingosine kinase activity. First author DOI 10.1016/s1499-3872(11)60032-5↗
  19. Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro. Last author DOI 10.1111/j.1440-1746.2011.06778.x↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hongyu Li · 15 shared papers, 2011–2021 · strength 1.10
  2. Jiang Chen · 4 shared papers, 2014–2021 · strength 0.38
  3. Xu Liu · 3 shared papers, 2014–2021 · strength 0.30
  4. Xiaodong Shao · 4 shared papers, 2014–2018 · strength 0.28
  5. Jiajun Zhao · 4 shared papers, 2011–2017 · strength 0.21
  6. Xingshun Qi · 2 shared papers, 2016–2018 · strength 0.17
  7. Hao Han · 1 shared paper, 2021 · strength 0.17
  8. Chen Jiang · 1 shared paper, 2019 · strength 0.14
  9. Xu Liu · 1 shared paper, 2019 · strength 0.14
  10. Linan Ren · 2 shared papers, 2014–2015 · strength 0.12
  11. Chunyan Wu · 2 shared papers, 2014 · strength 0.10
  12. Wenda Xu · 1 shared paper, 2017 · strength 0.09
  13. Lisheng Wang · 2 shared papers, 2011–2013 · strength 0.07
  14. Hui Yao · 1 shared paper, 2015 · strength 0.06
  15. Yingyi Li · 1 shared paper, 2015 · strength 0.06
  16. Chen Jiang · 1 shared paper, 2015 · strength 0.06
  17. Zhigang Hu · 1 shared paper, 2013 · strength 0.06
  18. Xu Liu · 1 shared paper, 2013 · strength 0.06
  19. Xueyan Li · 1 shared paper, 2014 · strength 0.06
  20. Yingwei Sun · 1 shared paper, 2014 · strength 0.06
  21. Di Wang · 1 shared paper, 2014 · strength 0.05
  22. Ying-Yi Li · 1 shared paper, 2015 · strength 0.05
  23. Naofumi Mukaida · 1 shared paper, 2015 · strength 0.05
  24. Yao Hua Song · 1 shared paper, 2015 · strength 0.05
  25. Chen Liang · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.